{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:24:31Z","timestamp":1775031871779,"version":"3.50.1"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin intervent Radiol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venous thromboembolic disease (VTE) is a major cause of morbidity and mortality worldwide, consisting of both deep vein thrombosis (DVT) and pulmonary embolism (PE). Therapeutic anticoagulation is the primary treatment for acute VTE with the therapeutic goals of reducing proximal DVT embolization, inhibiting propagation or formation of new or recurrent VTE, and reducing mortality in patients with PE. Direct oral anticoagulants (DOACs) are now considered first-line therapy for most patients with acute VTE, though parenteral therapy and vitamin K antagonist (VKAs) remain as the preferred option in select patient groups. This study practically summarizes the medical management of acute VTE for interventionalists, focusing on the choice of agent amongst common pharmacologic therapies as well as the optimal duration of therapy based on risk factors for recurrent VTE.<\/jats:p>","DOI":"10.1055\/s-0045-1813235","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:28:27Z","timestamp":1764721707000},"page":"558-562","source":"Crossref","is-referenced-by-count":1,"title":["Medical Management of Acute Venous Thromboembolism"],"prefix":"10.1055","volume":"42","author":[{"given":"Cy R.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Chiu","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirish A.","family":"Kishore","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"M D Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"J A Heit","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"S 03","key":"ref3","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1513\/AnnalsATS.201509-619AS","article-title":"From acute to chronic thromboembolic disease","volume":"13","author":"T Fernandes","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association","volume":"103","author":"J Hirsh","year":"2001","journal-title":"Circulation"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2022.16815","article-title":"Acute pulmonary embolism: a review","volume":"328","author":"Y Freund","year":"2022","journal-title":"JAMA"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jtha.2025.01.009","article-title":"Basics of diagnosis and treatment of venous thromboembolism","volume":"23","author":"C Cox","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/jama.2009.853","article-title":"Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review","volume":"301","author":"J B Segal","year":"2009","journal-title":"JAMA"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-012-1059-0","article-title":"Protein C anticoagulant and cytoprotective pathways","volume":"95","author":"J H Griffin","year":"2012","journal-title":"Int J Hematol"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-107-4-441","article-title":"Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial","volume":"107","author":"D J Doyle","year":"1987","journal-title":"Ann Intern Med"},{"issue":"7138","key":"ref10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"D W Barritt","year":"1960","journal-title":"Lancet"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJM197910183011602","article-title":"Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis","volume":"301","author":"R Hull","year":"1979","journal-title":"N Engl J Med"},{"issue":"19","key":"ref12","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021","volume":"166","author":"S M Stevens","year":"2024","journal-title":"Chest"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism","volume":"393","author":"G Piazza","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"H R B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"ref17","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"S Schulman","year":"2014","journal-title":"Circulation"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"C D Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-024-03648-y","article-title":"Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data","volume":"80","author":"M ME Diesveld","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"08","key":"ref21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study","volume":"118","author":"N Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"G F Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tmrv.2021.06.007","article-title":"Roles of four-factor prothrombin complex concentrate in the management of critical bleeding","volume":"35","author":"K A Tanaka","year":"2021","journal-title":"Transfus Med Rev"},{"issue":"19","key":"ref24","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"S J Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"D A Garcia","year":"2012","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"C Kearon","year":"2008","journal-title":"Chest"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"W Lim","year":"2006","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"G Lu","year":"2013","journal-title":"Nat Med"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"N R Bijsterveld","year":"2004","journal-title":"Br J Haematol"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH12-08-0575","article-title":"Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats","volume":"109","author":"G Corbonnois","year":"2013","journal-title":"Thromb Haemost"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"M A Rodger","year":"2017","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"F Couturaud","year":"2025","journal-title":"Lancet"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0042-1757340","article-title":"Antithrombotic therapy after deep venous intervention","volume":"39","author":"N Xiao","year":"2022","journal-title":"Semin Intervent Radiol"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2214\/AJR.22.27413","article-title":"Antithrombotic therapy after venous interventions: AJR expert panel narrative review","volume":"219","author":"S Kishore","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejvs.2018.01.007","article-title":"Antithrombotic therapy following venous stenting: international delphi consensus","volume":"55","author":"K Milinis","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/CIRCULATIONAHA.124.073050","article-title":"Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: the multicenter, multinational, randomized, open-label ARIVA trial","volume":"151","author":"S Barco","year":"2025","journal-title":"Circulation"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jth.15197","article-title":"Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: a systematic review","volume":"19","author":"P Notten","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1813235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:36:17Z","timestamp":1766187377000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1813235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,12,19]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1813235","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0739-9529","1098-8963"],"issn-type":[{"value":"0739-9529","type":"print"},{"value":"1098-8963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}